Inflammatory cardiomyopathy: state-of-the-art


Cite item

Full Text

Abstract

Cardiomyopathy (CMP) is a major cause of early disability and death in young cardiac patients, remaining at the same time a little studied problem. The generally accepted term "dilated cardiomyopathy" is only a portrayal of morphological signs. As of now, the foreign literature most commonly uses the term "inflammatory cardiomyopathy" to denote CMP caused by viral and/or bacterial agents. Owing to the wide use of novel laboratory and instrumental diagnostic techniques, namely: molecular genetic and immunohistochemical studies and endomyocardial biopsy, there has been a possibility to conduct a more accurate and fuller study of inflammatory CMP. Despite the fact that the problems in nosology, classification, choice of the optimal diagnostic methods and management tactics for these patients.

About the authors

E A Belyavsky

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow

Email: belyavskiy@cardio.ru
Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow

K A Zykov

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow

O Yu Narusov

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow

V P Masenko

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow

A A Skvortsov

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow

A Yu Shchedrina

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow

S N Tereshchenko

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow

References

  1. Taylor D. O., Edwards L. B., Boucek M. M. et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report - 2005. J. Heart Lung. Transplant. 2005; 24: 945-955.
  2. Фомин И. В., Беленков Ю. Н., Мареев В. Ю. и др. Распространенность хронической сердечной недостаточности в европейской части Российской Федерации - данные ЭПОХА-ХСН. Серд. недостаточ. 2006; 7 (1): 4-7.
  3. Libby P., Zipes D., Bonow R. et al. Braunwald's heart disease. A textbook of cardiovascular medicine. 8th ed. Philadelphia: W. B. Saunders Company; 2007.
  4. Brigden W. Uncommon myocardial diseases: the noncoronary cardiomyopathies. Lancet 1957; 273: 1179-1184.
  5. Goodwin J. F., Gordon H., Hollman A., Bishop M. B. Clinical aspects of cardiomyopathy. Br. Med. J. 1961; 5219: 69-79.
  6. Report of the WHO/ISFC Task Force on the definition and classification of cardiomyopathies. Br. Heart J. 1980; 44: 672- 673.
  7. Magnani J. W., Deg G. W. Myocarditis: Current Trends in Diagnosis and Treatment. Circulation 2006; 113: 876-890.
  8. Baboonian C., Treasure T. Meta-analysis of the association of enteroviruses with human heart disease. Heart 1997; 78: 539- 543.
  9. Maisch B., Richter A., Koelsch K. et al. Management of Patients with Suspected (Peri-) Myocarditis and Inflammatory Dilated Cardiomyopathy. Herz 2006; 31: 881-890.
  10. Maisch B., Richter A., Sandmoller A. et al. BMBF-Heart Failure Network: Inflammatory dilated cardiomyopathy (DCMI). Herz 2005; 30: 535-544.
  11. Angelow A., Weitmann K., Schmidt M. et al. The German Transregional Collaborative Research Centre "Inflammatory Cardiomyopathy - Molecular Pathogenesis and Therapy". Cardiology 2009; 113: 222-230.
  12. Kim K.-S., Hofling K., Carson S. D. et al. The primary viruses of myocarditis. In: Cooper L. T. ed. Myocarditis: from bench to beside. Totowa, New Jersey: Humana Press; 2003. 23-54.
  13. Pankuweit S., Baandrup U., Moll R. et al. Prevalence of parvovirus B19 genome in endomyocardial biopsy specimen. Hum. Pathol. 2003; 34: 80-86.
  14. Orinius E. The late cardiac prognosis after Coxsackie-B infection. Acta Med. Scand. 1968; 183: 235-237.
  15. Сторожаков Г. И., Гендлин Г. Е., Тронина О. А. Миокардиты. Серд. недостат. 2009; 10 (1): 46-52.
  16. Ellis C. R., Di Salvo T. Myocarditis: basic and clinical aspects. Cardiol. Rev. 2007; 15: 170-177.
  17. Takeda N. Cardiomyopathy: molecular and immunological aspects (review). Int. J. Mol. Med. 2003; 11 (1): 13-16.
  18. Коваленко В. Н., Несукай Е. Г., Чернюк С. В. Миокардит: новые подходы к решению актуальной проблемы. Українськ. ревматологїч. журн. 2009; 1 (35): 11-16.
  19. Mason J. W. Myocarditis and dilated cardiomyopathy: An inflammatory link. Cardiovasc. Res. 2003; 60: 5-10.
  20. Liu P. P., Mason J. W. Advances in the understanding of myocarditis. Circulation 2001; 104: 1076-1082.
  21. Гиляревский С. Р. Миокардиты: современные подходы к диагностике и лечению. М.: Медиасфера; 2008.
  22. Dennert R., Crijns H. L., Heymans S. Acute viral myocarditis. Eur. Heart J. 2008; 29: 2073-2082.
  23. Kühl U., Pauschinger M., Seeberg B. et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112: 1965-1970.
  24. Bowles N. E., Ni J., Kearney D. L. et al. Detection of viruses in myocardial tissues by polymerase chain reaction: evidence of adenovirus as a common cause of myocarditis in children and adults. J. Am. Coll. Cardiol. 2003; 42: 466-472.
  25. Badorff C., Berkely N., Mehrotra S. et al. Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue. J. Biol. Chem. 2000; 275 (15): 11191-11197.
  26. Kerr J. F., Saraste A., Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc. Res. 2000; 45: 528-537.
  27. Feldman A. M., McNamara D. Myocarditis. N. Engl. J. Med. 2000; 343: 1388-1398.
  28. Kawai C. From myocarditis to cardiomypathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 1999; 99: 1091-1100.
  29. Kytö V., Saraste A., Saukko P. et al. Apoptotic Cardiomyocite Death in Fatal Myocarditis. Am. J. Cardiol. 2004; 94: 746- 750.
  30. Yeh E. T. H. Autoimmunity and the Pathogenesis of Myocarditis. Circulation 1994; 89: 1318-1319.
  31. Pankuweit S., Portig I., Maisch B. et al: Pathophysiology of cardiac inflammation: Molecular mechanisms. Herz 2002; 27: 669-676.
  32. Pankuweit S., Portig I., Lottspeich F. et al. Autoantibodies in the sera of patients with myocarditis: Characterization of the corresponding antigens by isoelectric focussing and n-terminal sequence analysis. J. Mol. Cell Cardiol. 1997; 29: 77-84.
  33. Maisch B., Ristic A., Hufnagel G. et al. Pathophysiology of viral myocarditis. The role of humoral immune response. Cardiovasc. Pathol. 2002; 11: 112-122.
  34. Pankuweit S., Ruppert V., Maisch B. Inflammation in dilated cardiomyopathy. Herz 2004; 29: 788-793.
  35. Why H. J., Meany B. T., Richardson P. J. et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 1994; 89: 2582-2589.
  36. Наумов В. Г. Клинико-инструментальная характеристика, дифференциальная диагностика и прогноз больных ДКМП (результаты 15-летнего проспективного наблюдения): Дис. ... д-ра мед. наук. М. 1995.
  37. Терещенко С. Н. Дилатационная кардиомиопатия сегодня. Consilium Medicum 2001; 3 (2): 3-9.
  38. Карпов Ю. А., Сорокин Е. В. Миокардиты в клинической практике: современные представления о старой болезни. Рус. мед. журн. 2001; 9 (10): 423-427.
  39. Бойцов С. А., Дерюгин М. В. Современные возможности диагностики неревматических миокардитов. Consilium Medicum 2002; 4 (3): 117-124.
  40. Мравян С. Р., Гуревич М. А. Особенности клиники, диагностики и лечения миоперикардитов и диффузных миокардитов. Рос. кардиол. журн. 2003; 5: 99-103.
  41. Мухарлямов Н. М., Попович М. И., Затушевский И. Ф. Дилатационная кардиомиопатия. Кишинев: Штиинца; 1986.
  42. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996: 841-842.
  43. Maron B. J., Towbin J. A., Thiene G. et al. Contemporary definitions and classification of the cardiomyopathies. Circulation 2006; 113: 1807-1816.
  44. Моисеев В. С., Киякбаев Г. К. Проблема классификации кардиомиопатий. Кардиология 2009; 49 (1): 65-70.
  45. Elliott P., Andersson B., Arbustini E. et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 2008; 29: 270-276.
  46. Maron B. J.. The 2006 American Heart Association Classification of Cardiomyopathies Is the Gold Standard. Circ. Heart Fail. 2008; 1: 72-76.
  47. Elliott P. The 2006 American Heart Association Classification of Cardiomyopathies Is Not the Gold Standard. Circ. Heart Fail. 2008; 1: 77-80.
  48. Dec G. W. Introduction to clinical myocarditis. In: Cooper L. T., ed. Myocarditis from bench to beside. Totowa, New Jersey: Humana Press; 2003. 257-281.
  49. Ройтберг Г. Е., Струтынский А. В. Внутренние болезни. Сердечно-сосудистая система. М.: БИНОМ; 2003. 744- 746.
  50. Cook S. A., Rosenzweig A. DNA microarrays: implications for cardiovascular medicine. Circ. Res. 2002; 91: 559-564.
  51. Napoli C., Lerman L. O., Sica V. et al. Microarray analysis: a novel research tool for cardiovascular scientists and physicians. Heart 2003; 89: 597-604.
  52. Henriksen P. A., Kotelevtsev Y. Application of gene expression profiling to cardiovascular disease. Cardiovasc. Res. 2002; 54: 16-24.
  53. Slonim D. K. From patterns to pathways: gene expression data analysis comes of age. Nat. Genet. 2002; 32: 502-508.
  54. Jin O., Sole M. J., Butany J. W. et al. Detection of enterovirus RNA in myocardial biopsies from patients with myocarditis and cardiomyopathy using gene amplification by polymerase chain reaction. Circulation 1990; 82: 8-16.
  55. Hauck A. J., Kearney D. L., Edwards W. D. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin. Proc. 1989; 64: 1235-1245.
  56. Cooper L. T. et al. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease. A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. J. Am. Coll. .Cardiol. 2007; 50 (19): 1914-1931.
  57. Deckers J. W., Hare J. M., Baughman K. M. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. J. Am. Coll. Cardiol. 1992; 19: 43-47.
  58. Shirani J., Freant L. J., Roberts W. C. Gross and semiquantitative histologic findings in mononuclear cell myocarditis causing sudden death, and implications for endomyocardial biopsy. Am. J. Cardiol. 1993; 72: 952-957.
  59. Aretz H. T., Billingham M. E., Edwards W. D. et al. Myocarditis. A histopathologic definition and classification. Am. J. Cardiovasc. Pathol. 1987; 1: 3-14.
  60. Aretz H. T. Myocarditis: The Dallas criteria. Hum. Pathol. 1987; 18 (6): 619-624.
  61. Hahn E. A., Hartz V. L., Moon T. E. et al. The Myocarditis Treatment Trial: design, methods and patients enrollment. Eur. Heart J. 1995; 16: 162-167.
  62. Parrillo J. E. Inflammatory cardiomyopathy (myocarditis): which patients should be treated with anti-inflammatory therapy? Circulation 2001; 104: 4-6.
  63. Heymans S. Myocarditis and heart failure: need for better diagnostic, predictive and therapeutic tools. Eur. Heart J. 2007; 28: 1279-1280.
  64. Lieberman E. B., Hutchins G. M., Herskowitz A. et al. Clinicopathologic description of myocarditis. J. Am. Coll. Cardiol. 1991; 18: 1617-1626.
  65. Maish B., Portig I., Ristic A. et al. Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. A status report. Herz 2000; 25 (3): 200-209.
  66. Коваленко В. Н. Миокардит и дилатационная кардиомиопатия: проблемы диагностики и лечения. Українськ. кардїол. журн. 2004; 1: 35-40.
  67. Friedrich M. G., Sechtem U., Schulz-Menger J. et al. Cardiovascular Magnetic Resonance in Myocarditis. A JACC White Paper 2009; 53 (17): 1475-1487.
  68. Беленков Ю. Н., Терновой С. К., Синицын В. Е. Магнитно-резонансная томография сердца и сосудов. М.: Видар; 1997.
  69. Sarda L., Colin P., Boccara F. et al. Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms. J. Am. Coll. Cardiol. 2001; 37: 786-92.
  70. Dec G. W., Palacios I., Yasuda T. et al. Antimyosin antibody cardiac imaging: its role in the diagnosis of myocarditis. J. Am. Coll. Cardiol. 1990; 16: 97-104.
  71. Cooper L. T., Baughman K. L., Feldman A. M. The role of endomyocardial biopsy in the management of cardiovascular disease. Eur. Heart J. 2007; 28: 3076-3093.
  72. Schultheiss H.-P., Kühl U. Overview on chronic viral cardiomyopathy/chronic myocarditis. In: Schultheiss H.-P., Kapp J.-F., Grötzbach G., ed. Chronic viral and inflammatory cardiomyopathy. Berlin; Heidelberg: Springer 2007. 3-18.
  73. Mason J. W., O'Connell J. B., Herskowitz A. et al. A clinical trial of immunosuppressive therapy for myocarditis. N. Engl. J. Med. 1995; 333: 269-275.
  74. Maisch B., Herzum M., Hufnagel G. et al. Immunosuppressive and immunomodulatory treatment for myocarditis. Curr. Opin. Cardiol. 1996; 11: 310-324.
  75. Maisch B., Hufnagel G., Schonian U. et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID). Eur. Heart J. 1995; 16 (suppl. 0): 173-175.
  76. Maisch B., Pankuweit S., Koelsch S. et al.; Sequential analysis of immunosuppressive therapy in autoreactive myocarditis - sequential Analysis from ESETCID. Circulation 2007; 116 (II): 337-338.
  77. Maisch B., Koelsch S., Hufnagel G. et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID) - intermediate analysis of immunosuppressive therapy. Circulation 2007; 114 (II): 620.
  78. Frustaci A., Russo M. A., Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur. Heart J. 2009, 30: 1995-2002.
  79. Страчунский Л. С., Козлов С. Н. Современная антимикробная химиотерапия. Руководство для врачей. М.: Боргес; 2002.
  80. Kühl U., Pauschinger M., Lothar Schwimmbeck P. et al. Interferon-Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction. Circulation 2003; 107: 2793-2798.
  81. Miric M., Vasiljevic J., Bojic M. et al. Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones initial results. Heart 1996; 75: 596-601.
  82. Kühl U., Pauschinger M., Noutsias M. et al. Diagnosis and treatment of patients with virus induced inflammatory cardiomyopathy. Eur. Heart J. 2002; 4 (1): 173-180.
  83. Müllmann H., Nef H., Böhm M., Laufs U. Highlights of the hotline sessions presented at the scientific sessions 2008 of the American Heart Association Clin. Res. Cardiol. 2009; 98: 1- 7.
  84. Kishimoto C., Shioji K., Kinsohita M. et al. Treatment of acute inflammatory cardiomyopathy with intravenous immunoglobulin ameliorates left ventricular function associated with suppression of inflammatory cytokines and decreased oxidative stress. Int. J. Cardiol. 2003; 91: 173-178.
  85. McNamara D. M., Holubkov R., Starling R. C. et al. For the Intervention in Myocarditis and Acute Cardiomyopathy (IMAC) Investigators: Controlled trial of intravenous immune globuline in recent-onset dilated cardiomyopathy. Circulation 2001; 103: 2254-2259.
  86. Maisch B., Pankuweit S., Funck R. et al. Effective CMV hyperimmunoglobulin treatment in CMV myocarditis - a controlled treatment trial. Eur. Heart J. 2004; 25 (Abstr. Suppl. 1): 114: 674.
  87. Dörffel V., Stephan F., Wallukat G. et al. Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation 1997; 95: 1994-1995.
  88. Müller J., Wallukat G., Dandel M. et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101: 385-391.
  89. Seth S., Narang R., Bhargava B. Percutaneous Intracoronary Cellular Cardiomyoplasty for Nonischemic Cardiomyopathy: Clinical and Histopathological Results: The First-in-Man ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) Trial. J. Am. Coll. Cardiol. 2006; 48 (11): 2350-2359.
  90. Seth S., Bhargava B., Narang R. et al. A randomized trial of Autologous Bone Marrow Cells in Dilated Cardiomyopathy (ABCD). Eur. J. Heart Fail. 2009; Suppl. 2009; 8(2): 5-10.
  91. GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231- 1239.
  92. Wojnicz R., Wilczek K., Nowalany-Kozielska E. et al. Usefulness of Atorvastatin in Patients With Heart Failure Due to Inflammatory Dilated Cardiomiopathy and Elevated Cholesterol Levels. Am. J. Cardiol. 2006; 97: 899-904.
  93. Беленков Ю. Н., Татенкулова С. Н., Мареев В. Ю. и др. Иммунокорригирующие свойства статинов в лечении дилатационной кардиомиопатии. Сердеч. недостат. 2008; 6: 268-273.
  94. Маркова Т. П. Иммунотропные препараты в клинической практике. В кн.: Хаитов Р. М. (ред.) Практическое пособие по клинической иммунологии и аллергологии. М.; 2003. 31-45.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies